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Purpose: Analysis of the sentinel lymph node (SLN) in colorectal cancer (CRC) patients was proposed for more accurate 
staging and tailored lymphadenectomy. The aim of this study was to assess the ability to predict lymph node (LN) involve-
ment through analysis of the SLN with a one-step nucleic acid (OSNA) technique in combination with peritumoral injec-
tion of indocyanine green (ICG) and near-infrared (NIR) lymphangiography in CRC patients.
Methods: A total of 34 patients were enrolled. Overall, 51 LNs were analyzed with OSNA. LNs of 17 patients (50%) were 
examined simultaneously with hematoxylin and eosin (H&E) and OSNA. 
Results: SLN analysis of 17 patients examined with H&E and OSNA revealed that OSNA had a higher sensitivity (1 vs. 
0.55), higher negative predictive value (1 vs. 0.66) and higher accuracy (100% vs. 76.4%) in predicting LN involvement. 
Overall, OSNA showed a sensitivity of 0.69, specificity of 1, accuracy of 88.2%, and stage migration of 8.8%. Compared to 
those who were OSNA (−), OSNA (+) patients had a greater number of LN metastases (4.8 vs. 0.16, P = 0.04), higher G3 
rate (44.4% vs. 4%, P = 0.01), more advanced stage of disease (stage III: 77.8% vs. 16%; P = 0.00) and were more rapidly 
subjected to adjuvant chemotherapy (39.1 days vs. 50.2 days, P = 0.01). 
Conclusion: SLN analysis with OSNA in combination with ICG-NIR lymphangiography is feasible and can detect LN in-
volvement in CRC patients. Furthermore, it allows for more accurate staging reducing the delay between surgery and ad-
juvant chemotherapy.
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common cancer world-
wide and lymph node (LN) status is the most powerful prognostic 
factor [1, 2]. After curative treatment, between 30% and 65% of 
patients with CRC will develop recurrent disease [3]. Under-stag-
ing for CRC patients is thought to occur in around 10%–20% of 
patients and the relevant literature shows that examination of only 
one LN slide using hematoxylin and eosin (H&E) staining leaves 
up to 33% of metastases unidentified [4].
Moreover, some studies have shown that extensive lymphade-
nectomy is associated with improved prognosis in patients with 
more advanced stage CRC, even though numerous postoperative 
complications related to this extensive surgery are described [5, 6]. 
On the other hand, organ-preserving surgery without lymphade-
nectomy has been proposed for early-CRC with encouraging re-
sults [7, 8]. 
Among colorectal surgeons and treatments, it is now accepted 
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that “one size does not fit all,” and there is increasing agreement 
regarding the need for a more targeted surgery and a tailored 
lymphadenectomy [9]. 
The challenge is the careful selection of patients; early CRC dis-
ease could benefit from organ-preserving surgery while more ad-
vanced stage disease would require tailored lymphadenectomy 
taking into consideration LN status, the presence of aberrant lym-
phatic drainage and “skip” metastases.
The sentinel lymph node (SLN) is defined as the first LN in the 
lymphatic basin that drains the primary tumor, and it has recently 
been proposed as a strategy for more precise staging in gastroin-
testinal tumors [10]. Some groups have demonstrated that peritu-
moral injection of indocyanine green (ICG) with near-infrared 
(NIR) provides for visualization of LNs and aberrant lymphatic 
drainage during CRC resection [11]. Furthermore, a novel tech-
nique for SLN analysis has been developed: one-step nucleic acid 
amplification (OSNA; Sysmex Corp., Kobe, Japan) is a rapid 
mRNA assay that by measuring levels of cytokeratin 19 (CK19) 
can to identify the presence of metastases and micro-metastases 
in the LNs within 30–40 minutes of their removal [12]. 
The aims of this pilot study were to assess the ability to predict 
LN involvement in patients with CRC using SLN analysis with 
OSNA in combination with ICG-NIR lymphangiography and to 
estimate the benefits of the routine use of this technique.
METHODS
Study design and population
This cohort study relies on data retrieved from a prospectively 
maintained database of consecutive patients undergoing elective 
colorectal resection for adenocarcinoma at St. Giuseppe Moscati 
Hospital of Avellino, Italy. The database was implemented in 2016 
and included preoperative, operative, and postoperative data. In-
clusion criteria were any adult patients diagnosed with CRC re-
quiring surgical treatment. Exclusion criteria included partici-
pants with an allergy to any ICG. In total, 34 patients were in-
cluded in this study. 
The study was conducted according to the ethical principles of 
the Institution following the Declaration of Helsinki and was ap-
proved by the Institutional Review Board of the St. Giuseppe 
Moscati Hospital (approval number: 201801). Written informed 
consent was granted by study participants for publication of this 
article.
Surgical technique and histopathological evaluation
All patients underwent colonic preparation within 3 days prior to 
surgery. Immediately after access to the abdominal cavity by lapa-
rotomy or laparoscopy, a flexible endoscope was passed to the tu-
mor site to allow a 1- to 2-mL submucosal injection of ICG (2.5–5 
mg/mL) in four points around the tumor. The mesocolic or me-
sorectal tissue was then examined under NIR illumination (KARL 
STORZ SE & Co., Tuttlingen, Germany) and any identifiable LNs 
were excised and submitted immediately to the pathology depart-
ment (Fig. 1). The retrieved LNs were staged according to the 
classification system of the Japanese Society for Cancer of the Co-
lon and Rectum [13]. LNs harvested in this way were cleaned of 
fat, frozen in liquid nitrogen and stored at −80°C for processing. 
LNs weighing between 0.05 g and 0.6 g or with a cross diameter 
of less than 8 mm were exclusively processed using the OSNA 
technique. LNs weighing more than 0.6 g or more than 8 mm in 
diameter were dissected and analyzed using both the OSNA and 
H&E methods. In the latter case, LNs were divided at 2-mm in-
tervals, and nonadjacent blocks were alternatively subjected to 
histopathological examination with H&E or OSNA as described 
by Yamamoto et al. [14]. For the OSNA assay, larger LNs or slices 
of smaller LNs were placed in homogenized lysis buffer (Ly-
Fig. 1. Procedure for identification of the sentinel lymph node (SLN). (A) Endoscopic submucosal injection of indocyanine green (2.5–5 mg/
mL) in 4 points around the tumor. (B) A blue arrow indicates the SLN identified with near-infrared during surgery. (C) A blue arrow indicates 
the LN harvested and submitted to the pathology department.
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Table 1. Clinicopathologic characteristics of patients according to OSNA status
Characteristic All patients (n = 34) OSNA (−) (n = 25) OSNA (+) (n = 9) P-value
Age (yr) 69.3 ± 11.8 71 ± 9.9 64.6 ± 15.8 0.82
Male sex 21 (61.8) 16 (64.0) 5 (55.6) 0.70
Body mass index (kg/m2) 24.8 ± 2.7 25.1 ± 2.3 23.9 ± 3.4 0.33
Tumor location
   Right colon 10 (29.4) 6 (24.0) 4 (44.4) 0.39
   Left colon 11 (32.4) 8 (32.0) 3 (33.3) 1.00
   Rectum 13 (38.2) 11 (44.0) 2 (22.2) 0.42
Neoadjuvant chemotherapy 2 (5.9) 0 (0) 2 (22.2) 0.06
Surgical approach
   Open 26 (76.5) 17 (68.0) 9 (100) 0.07
   Laparoscopic 8 (23.5) 8 (32.0) 0 (0)
Stadiation 
   pT stage
      pT1–pT2 9 (26.5) 9 (36.0) 0 (0) 0.07
      pT3–pT4 25 (73.5) 16 (64.0) 9 (100) 0.07
   pN stage
      Negative 21 (61.8) 21 (84.0) 0 (0) 0.00*
      Positive 13 (38.2) 4 (16.0) 9 (100)
Sentinel lymph node number examined 1.5 ± 0.6 1.5 ± 0.7 1.3 ± 0.5 0.31
Total lymph node number 19.9 ± 11.1 18.2 ± 10.2 24.7 ± 12.9 0.19
Metastatic lymph node number 1.38 ± 3.5 0.16 ± 0.3 4.8 ± 5.8 0.04*
>3 Metastatic lymph nodes 3 (8.8) 0 (0) 3 (33.3) 0.01*
Lymph node level (JSCCR)
   1 12 (35.2) 7 (28.0) 5 (55.6) 0.22
   2 11 (32.4) 8 (32.0) 3 (33.3) 1.00
   3 11 (32.4) 10 (40.0) 1 (11.1) 0.21
M1 2 (5.9) 0 (0) 2 (22.2) 0.06
Histological grade
   G1 (well differentiated) 1 (2.9) 1 (4.0) 0 (0) 1.00
   G2 (moderate differentiated) 28 (82.4) 23 (92.0) 5 (55.6) 0.03*
   G3 (poorly differentiated) 5 (14.7) 1 (4.0) 4 (44.4) 0.01*
Stage
   I 7 (20.6) 7 (28.0) 0 (0) 0.15
   II 14 (41.2) 14 (56.0) 0 (0) 0.00*
   III 11 (32.4) 4 (16.0) 7 (77.8) 0.00*
   IV 2 (5.9) 0 (0) 2 (22.2) 0.06
Adjuvant chemotherapy 12 (35.3) 4 (16.0) 8 (88.9) 0.00*
Time to start adjuvant chemotherapy (day) 42.8 ± 6.1 50.2 ± 4.1 39.1± 1.9 0.01*
Values are presented as mean ± standard deviation or number (%).
OSNA, one-step nucleic acid; JSCCR, Japanese Society for Cancer of the Colon and Rectum. 
*P < 0.05, significant difference.
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norhag, Sysmex) and then centrifuged. Lysate was then extracted 
for CK19 mRNA RT-LAMP in the RD-100i system (Sysmex) us-
ing the Lynoamp (Sysmex) reagent kit [15]. On the basis of previ-
ous investigations, OSNA results with CK19 mRNA above 250 
copies/L were designated as positive and those with fewer than 
250 copies/L were considered negative [12]. The result of the SLN 
analysis was intraoperatively communicated to the surgeon but 
the surgical procedure was not modified. All patients underwent 
standard CRC resection in the conventional manner. A total or 
partial mesocolon or mesorectal excision was performed. Subse-
quently, records of each patient were discussed in a multidisci-
plinary conference with surgeons, pathologists and oncologists, 
taking into consideration the definitive examination of the surgi-
cal specimen and the result of the SLN analysis. The final histol-
ogy of the surgical specimen and harvested LN were always con-
cluded based on H&E analysis.
Statistical analysis
Statistical analyses were carried out by dividing the study popula-
tion into 2 groups based on the results of the SLN analysis with 
OSNA. Continuous variables are presented as the mean ± stan-
dard deviations and were compared using Student t-test or the 
nonparametric Mann-Whitney test, as appropriate. Categorical 
variables are presented as numbers (percentages) and were com-
pared across groups using the chi-square test or Fisher exact test, 
as appropriate. Furthermore, sensitivity, specificity, positive pre-
dictive value (PPV), negative predictive value (NPV), and test ac-
curacy were calculated comparing the intraoperative result of 
OSNA with the definitive examination of all LNs detected in the 
surgical specimen, as routinely determined by the pathologist. All 
statistical analyses were performed with IBM SPSS Statistics ver. 
23.0 (IBM Co., Armonk, NY, USA).
RESULTS
Study population
The characteristics of all patients are shown in Table 1. Thirty-
four patients with colorectal adenocarcinoma were included in 
this study. Intraoperative evaluation of the SLN with OSNA was 
positive (OSNA [+]) in 9 patients (26.5%) and negative (OSNA 
[−]) in 25 patients (73.5%). No complications related to ICG in-
jection occurred during surgery. Globally, 51 LNs were retrieved 
and examined with a median of 1 (1–3) LN harvested for each 
patient. 
In 17 patients (50%), the SLN weighed more than 0.6 g or had a 
diameter greater than 8 mm, making LN evaluation possible with 
both OSNA and H&E as described. Comparing definitive histol-
ogy with simultaneous analysis of retrieved fresh LN with OSNA 
and H&E, the OSNA technique had higher sensitivity (95% con-
fidence interval [CI]), 1 (0.77–1.00) vs. 0.55 (0.30–0.78), a higher 
NPV (95% CI), 1 (0.77–1.00) vs. 0.66 (0.40–0.86), and higher ac-
curacy, 100% vs. 76.4%. Both methods showed high specificity 
(95% CI), 1 (0.77–1.00) vs. 1 (0.77–1.00), and a high PPV (95% 
CI), 1 (0.77–1.00) vs. 1 (0.77–1.00) (Tables 2 and 3).
Overall, comparing the definitive histology with OSNA analysis 
of retrieved fresh SLN of all patients, OSNA had a sensitivity (95% 
CI) of 0.69 (0.51–0.81), specificity (95% CI) of 1 (0.87–1.00), and 
accuracy of 88.2%. Its PPV (95% CI) was 1 (0.87–1.00), and its 
NPV (95% CI) was 0.84 (0.66–0.93) (Table 4). A summary of the 
sensitivity, specificity, PPV, and NPV are shown in Table 5.
Study OSNA (+) vs. OSNA (−) population characteristics
OSNA (+) and OSNA (−) patients were statistically similar in age 
(P = 0.82), sex (P = 0.70), BMI (P = 0.33), primary disease (P = 
0.39 for right colon, P = 1.00 for left colon and P = 0.42 for rectal 
cancer) and the number of patients undergoing neoadjuvant che-
motherapy (22.2% vs. 0%, P = 0.06) (Table 1). No statistically sig-
nificant difference was found between the 2 groups in surgical ap-
proach, but 100% of the procedures for patients in the OSNA (+) 
group were performed by laparotomy (P = 0.07). In 100% (vs. 
16%) of patients in the OSNA (+) group, pN was positive on de-
finitive histological examination (P = 0.00). Globally, 69.2% (9 of 
13) of patients with pN positive on definitive histological exami-
nation were identified during surgery. Yet, a greater number of 
LNs metastases were found in OSNA (+) patients (4.8 ± 5.8 vs. 
0.16 ± 0.3, P = 0.04). Moreover, 33.3% (vs. 0%) of patients in the 
Table 2. Comparing definitive histology with OSNA analysis of re-
trieved fresh lymph nodes also evaluated with hematoxylin and eosin
OSNA Histology (+) Histology (−) Total
(+) 9 0 9
(−) 0 8 8
Total 9 8 17
OSNA, one-step nucleic acid.
Table 3. Comparing definitive histology with H&E analysis of re-
trieved fresh lymph nodes also evaluated with one-step nucleic acid
H&E Histology (+) Histology (−) Total
(+) 5 0 5
(−) 4 8 12
Total 9 8 17
H&E, hematoxylin and eosin.
Table 4. Comparing definitive histology with OSNA analysis of all 
retrieved fresh lymph nodes
OSNA Histology (+) Histology (−) Total
(+) 9 0 9
(−) 4 21 25
Total 13 21 34
OSNA, one-step nucleic acid.
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OSNA (+) group had more than 3 metastatic LNs (P = 0.01). Re-
garding grading of the tumor, patients with OSNA (−) had a 
higher rate of G2 (moderately differentiated) (92% vs. 55.6%, P = 
0.03), while patients who were OSNA (+) had a higher G3 (poorly 
differentiated) rate (44.4% vs. 4%, P = 0.01). A higher number of 
patients in the OSNA (+) group had distant metastases OSNA (+), 
though the difference did not reach statistically significance 
(22.2% vs. 0%, P = 0.06). Globally, OSNA (+) patients had more 
advanced stages of disease (stage III: 77.8% vs. 16%, P = 0.00; 
stage IV: 22.2% vs. 0%, P = 0.06). After a multidisciplinary discus-
sion, 3 patients (8.8%) with SLN positive by the OSNA method 
were considered pN positive and subjected to adjuvant chemo-
therapy. Adjuvant chemotherapy was administered in 88.9% of 
patients in the OSNA (+) group (vs. 16%, P = 0.00), and the time 
to start chemotherapy was lower OSNA (+) (39.1 ± 1.9 days vs. 
50.2 ± 4.1 days in the OSNA [−] group, P = 0.01). 
DISCUSSION 
In this study, we showed that intraoperative SLN analysis with 
OSNA in combination with ICG-NIR lymphangiography is safe, 
feasible and can predict the state of LN involvement in patients 
with CRC. Overall, OSNA showed a sensitivity of 69%, specificity 
of 100%, accuracy of 88.2%, PPV of 100%, negative predictive of 
84%, false negative rate of 30.7% (4 of 13) and stage migration of 
8.8% (3 of 34). Furthermore, 66.7% (8 of 12) of OSNA (+) pa-
tients received adjuvant chemotherapy more rapidly. 
LN status plays a crucial role in oncologic therapeutic strategies, 
and despite the use of increasingly sophisticated imaging tech-
niques, pre-operative metastatic LN identification in patients with 
CRC is unsatisfactory [16, 17]. 
Innovative organ preserving procedures such as transanal mini-
mally invasive surgery allow an adequate resection of early tumors 
without resorting to extensive interventions [18]. Nevertheless, it 
is estimated that 10%–20% of patients in stage T1 will have LN 
metastasis, and such patients subjected to a localized resection are 
undertreated [19]. In Japan, on the other hand, unlike in western 
countries, a lateral LN dissection in association with conventional 
total mesorectal excision is performed for advanced rectal cancers 
(T3–4), and although it is associated with sexual and urinary dys-
function, the risk of intrapelvic recurrence is reduced by 50%, and 
survival increases [5, 20, 21].
Particularly in the latter 2 cases, SLN mapping with ICG-NIR 
lymphangiography may allow the identification of a smaller num-
ber of LNs representing the tumor status of the entire nodal basin, 
directing the surgeon to perform a targeted lymphadenectomy in 
place of a more radical or conservative treatment. Furthermore, 
exhaustive analysis of the SLN facilitates a more accurate staging 
of patients and can influence the decision for adjuvant treatment.
Two results of our study should be highlighted. First, in 3 pa-
tients (8.8%), the SLN analysis was strongly positive by OSNA but 
negative by H&E evaluation. After multidisciplinary assessment, 
these patients were considered pN positive and subjected to mi-
gration from stage II to III. This type of approach could lead to 
more accurate staging of the disease, allowing patients to access 
adjuvant chemotherapy. In fact, we know that 25% of CRC pa-
tients in stage II will die from recurrent disease [22]. One of the 
most important risk factors is the presence of unidentified LN 
micrometastasis. Rahbari et al. [23] concluded in a recent meta-
analysis that the presence of LN micrometastasis is associated 
with poor overall survival and shorter disease-free survival in 
stage II CRC patients. SLN micro-metastasis can easily be missed 
by H&E evaluation [24, 25]. Only immunohistochemistry (IHC) 
or molecular biology techniques can detect micrometastatic dis-
semination without doubt, but they are laborious and time-con-
suming [25, 26]. OSNA allows detection of the specific mRNA of 
cytokeratins without classical nucleic acid extraction and purifica-
tion. Moreover, the analysis of four LNs takes only 40 minutes. 
Yamamoto et al. [14] found a 95% concordance rate between 
OSNA and classical histological analysis with H&E and IHC. Re-
cently, Miyake et al. [27] demonstrated that the ex vivo analysis of 
perirectal LNs by OSNA predicts LLN metastasis in advanced 
rectal cancer with a sensitivity of 100%, specificity of 86%, PPV of 
57% and NPV of 100%. Other studies and a meta-analysis have 
also confirmed the ability of the OSNA to predict LN involvement 
[28]. In our study, OSNA was superior to H&E in identifying LN 
metastases, with a false negative rate of 0% vs. 44.4% and accuracy 
of 100% vs. 76.4%, respectively.  
Another benefit we found was that OSNA (+) patients received 
adjuvant chemotherapy more rapidly, an advantage also found by 
other authors [29]. Indeed, although no definite cutoff has been 
established, the greater the delay in starting adjuvant chemother-
Table 5. Summary of sensitivity, specificity, positive predictive value, negative predictive value, and test accuracy
Variable No. Sensitivity (95% CI) Specificity (95% CI) Accuracy (%) PPV (95% CI) NPV (95% CI)
Comparing definitive histology with OSNA analysis of SLN 
also evaluated with H&E
17      1 (0.77–1.00) 1 (0.77–1.00) 100 1 (0.77–1.00)     1 (0.77–1.00)
Comparing definitive histology with H&E analysis of SLN 
also evaluated with OSNA
17 0.55 (0.30–0.78) 1 (0.77–1.00) 76.4 1 (0.77–1.00) 0.66 (0.40–0.86)
Comparing definitive histology with OSNA analysis of all 
retrieved SLN
34 0.69 (0.51–0.81) 1 (0.87–1.00) 88.2 1 (0.87–1.00) 0.84 (0.66–0.93)
CI, confidence interval; PPV, positive predictive value; NPV, negative predictive value; OSNA, one-step nucleic acid; H&E, hematoxylin and eosin; SLN, sentinel lymph node.
Annals of
Coloproctology
www.coloproctol.org
Volume 35, Number 4, 2019
Ann Coloproctol 2019;35(4):174-180
179
apy, the higher the risk of metastatic progression in patients with 
advanced CRC [30]. When we found LN metastasis during sur-
gery, we planned the placement of a port-a-cath 2 weeks after sur-
gery and started chemotherapy without necessarily waiting for 
the final pathologic reports.
The limitations of our study are the small number of patients 
and false-negative rate (30.7%). We attribute this latter result to 
the method of lymphangiography rather than OSNA. Emile et al. 
[31], in a recent meta-analysis that enrolled 12 articles and 248 
patients showed a median sensitivity of 73.7% (range, 0%–100%), 
median specificity of 100% (range, 0%–100%) and accuracy rates 
of 75.7% (range, 0%–100%) for the detection of metastatic SLN in 
CRC patients with the use of ICG and NIR combined with H&E 
and IHC examination [31]. Except for the higher accuracy rate of 
our study (88.2% vs. 75.7%), the remaining results are similar to 
those reported in this meta-analysis [31]. The site of the ICG in-
jection plays a vital role in determining the outcomes of the test. 
Emile et al. [31] in effect, have shown that combined subserosal 
and submucosal injection achieved 100% rates of sensitivity, spec-
ificity and accuracy. Thus far, we have only used submucosal ICG 
injection just before surgery and will try to modify our technique 
in order to improve sensitivity. A further limit for the routine use 
of OSNA is the price, which remains quite high.
In conclusion, SLN analysis with OSNA in combination with 
ICG-NIR lymphangiography is feasible and may allow intraoper-
ative prediction of LN status in patients with CRC. Furthermore, 
its implementation allows more precise staging, reducing the de-
lay between surgery and the onset of adjuvant chemotherapy. In 
our study, the results of SLN analysis did not influence surgical 
strategy, but OSNA and ICG-NIR lymphangiography could be 
used to develop customized surgery and tailored lymphadenec-
tomy in patients with CRC.
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